Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Regenerative medicine
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 238997
Patent Products or Patent Products shall mean any article, composition, apparatus, substance, chemical, material, method or service which is made, used or sold by Licensee which
incorporates technology transferred to Licensee pursuant to the confidential disclosure agreement between University and Licensee dated 9/1/93 for University File # 2146B and dated 10/10/93 for University File # 2429 and USC File # 2430.
IPSCIO Record ID: 183951
62/443,826 Methods, compositions and devices related to neural cell development
IPSCIO Record ID: 290553
University furthermore grants to Licensee the right to make, have made, distribute and sell clinical diagnostic products. Licensee shall continue to have the right to commercially exploit the licensed inventions as related to diagnostic laboratory services.
The original agreement states
University hereby grants Licensee the exclusive right to conduct various technical, pre-clinical, marketing, patent, and other studies on Products in the field of use during a six (6) month period commencing on the effective date of this Agreement (the option period). The option period may be extended by mutual written agreement of the parties.
In consideration of the royalties, and subject to the terms and conditions, as set forth in this Agreement and effective upon the earlier to occur of (i) written notification to University during the option period that Licensee desires to license the Patent(s), or (ii) expiration of the option period with no written notification given, University hereby grants to Licensee i. the exclusive worldwide license in the field of use to use the Patent to make, have made, use distribute, and sell the Product(s); and ii. the right to grant sublicenses to any Patent licensed hereunder, provided that any sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to sublicensees.
USC#2860, filing date 12/15/1999
Product or Products shall mean any article, composition, apparatus, substance, chemical, material, method or service which is made, used, distributed or sold by Licensee which
i. is covered in whole or in part by one or more pending or unexpired claims contained in a Patent in the country in which the Product(s) is made, used, distributed or sold;
ii. is manufactured using a method or process which is covered in whole or in part by one or more pending or unexpired claims contained in a Patent in the country in which (a) the Product(s) is made, use, distributed or sold, or (b) the method or process is used or sold;
iii. the use of which is covered in whole or in part by one or more pending or unexpired claims contained in a Patent in the country in which (a) the Product(s) is made, used, distributed or sold, or (b) the method or process is used or sold; or
iv. incorporates Information transferred to Licensee pursuant to the confidential disclosure agreement dated January 7, 2000 between University and Licensee (as the term Information is defined in said agreement).
RGI-1 enables Licensee to rapidly and reliably isolate RNA and DNA from FFPE tissues. RGI-1 generates molecular-based tumor analyses for use in guiding chemotherapy treatment for cancer patients.
IPSCIO Record ID: 257470
The Licensee acknowledges that the rights granted by it to Sublicensee pursuant to the Collaboration Agreement in respect of what is defined thereunder as the Second Product, the Licensee hereby declaring that what is defined as the First Product thereunder has never been and never will be developed, include the grant of rights to use Licensors rights in the Licensed Information and/or the Joint Patents.
The original agreement is non-exclusive.
The sublicense collaboration is for FGF or fibroblast growth factor variant.
The fibroblast growth factors are a family of cell signalling proteins that are involved in a wide variety of processes, most notably as crucial elements for normal development.
The Licensee focuses on modulating the fibroblast growth factor system to enable it to create solutions for tissue regeneration.